News and Press Releases
Press releases
Theralase® Completes Annual General and Special Meeting
Press ReleaseJune 12, 2025 Toronto, Ontario–(Newsfile Corp. – June 12, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation, sound and ...
Theralase® Annual General Meeting
Press ReleaseJune 5, 2025 Toronto, Ontario–(Newsfile Corp. – June 5, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation, sound and dru...
Theralase® 1Q2025 Financial Statements
Press ReleaseMay 30, 2025 Toronto, Ontario–(Newsfile Corp. – May 30, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation, sound and dru...
CORRECTION FROM SOURCE: Theralase® to Present Groundbreaking Research at ASTRO 2025
Press ReleaseMay 29, 2025 Radiation-Activated Rutherrin(R) Versus Radiation Alone in Preclinical Cancer Models to be Presented at ASTRO 2025 This Press Release removes references to preclinical data that has not yet been presented. Toronto, Ontario–(...
Theralase® to Present Groundbreaking Research at ASTRO 2025
Press ReleaseMay 28, 2025 Radiation-Activated Rutherrin(R) Shown to Be 100 Times More Effective Than Radiation Alone in Preclinical Cancer Models Toronto, Ontario–(Newsfile Corp. – May 28, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLT...
Theralase® Provides Corporate Update
Press ReleaseMay 20, 2025 Toronto, Ontario–(Newsfile Corp. – May 20, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development ...
Theralase® Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
Press ReleaseMay 5, 2025 Toronto, Ontario–(Newsfile Corp. – May 5, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of...
Theralase® Discovers New Mechanism of Action of Lead Drug
Press ReleaseApril 28, 2025 Theralase® Has Discovered a New Mechanism of Action in Its War on Cancer; Specifically, Ruvidar’s(TM) Ability to Inhibit DeUbiquitinating Enzymes, an Important Class of Enzymes Which Have Been Linked to Numerous Cancers a...
Theralase® Closes Non-Brokered Private Placement
Press ReleaseApril 14, 2025 Toronto, Ontario–(Newsfile Corp. – April 14, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and developm...
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Press ReleaseApril 10, 2025 RuvidarTM demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario–(Newsfile Corp....
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
